Inflammation and mood disorders: Proinflammatory cytokines and the pathogenesis of depression

Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry

Volumn 9, Issue 3, 2010, Pages 212-220

  Currier, M Beatriz ^a   Nemeroff, Charles B ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Cytokines; Depression; Hypothalamic pituitary adrenal axis; Inflammation; Monoamine neurotransmitters

Indexed keywords

ALPHA INTERFERON; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; DOPAMINE; ESCITALOPRAM; ETANERCEPT; GLUTAMINE; PAROXETINE; PLACEBO; REBOXETINE; SEROTONIN;

ARTICLE; BRAIN DEVELOPMENT; BRAIN REGION; CLINICAL TRIAL; COMORBIDITY; DEPRESSION; DISEASE ASSOCIATION; DOPAMINE METABOLISM; DOPAMINERGIC TRANSMISSION; DRUG MECHANISM; DRUG MEGADOSE; ELECTROENCEPHALOGRAM; GLUTAMATERGIC TRANSMISSION; HEPATITIS C; HIPPOCAMPUS; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INFLAMMATION; INNATE IMMUNITY; LOW DRUG DOSE; MAJOR DEPRESSION; MELANOMA; MENTAL STRESS; MOOD DISORDER; NERVE CELL PLASTICITY; NEUROTRANSMISSION; NONHUMAN; PATHOGENESIS; PROTEIN BLOOD LEVEL; SEROTONIN METABOLISM; SEROTONINERGIC TRANSMISSION;

EID: 77958450142     PISSN: 18715230     EISSN: None     Source Type: Journal    
DOI: 10.2174/1871523011009030212     Document Type: Article

References (122)

1. Murray, C.J.L. In The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Disease, Injuries and Risk Factors in 1990 and projected to 2020. Murray, J.L., Lopez, A.D., Eds.; Harvard University Press: USA, 1996.
2. Michaud, C. Burden of disease - implications for future research. JAMA., 2001, 285, 535-39.
3. Roy, A. Suicide and psychiatric patients. Psychiatr. Clin. N. Am., 1985, 8, 227-41.
4. Frasure-Smith, N. Depression following myocardial infarction.: impact on 6-month survival. JAMA, 1993, 270, 1819-25.
5. Williams, L.S. Depression and other mental health diagnoses Increase mortality risk after ischemic stroke. Am J Psychiatry, 2004, 161, 1090-95.
6. Dinan, T.G. Glucocorticoids and genesis of depressive illness: a psychobiological approach. Br J Psychiatry, 1994, 164, 365-71.
7. Green, A.J.; Mooney, J.J.; Poesner, J.A.; Schildkraut, J.J. in Comprehensive Textbook of Psychiatry, Kaplan H.H., Sadock, B.J., Ed.; Williams and Wilkins: Baltimore, 1995; Vol. VI, pp.1089-1102.
8. Raison, C.L.; Capuron, L.; Miller, A.H. Cytokines sing the blues: inflammation and the pathogenesis of major depression. Trend Immunol., 2006, 27, 24-31.
9. Dantzer, R.; O'Connor, J. C.; Freund, C. G.; Johnson, R. W.; Kelley, R. W. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci., 2008, 9, 46-56.
10. Miller, A.H.; Maletic, V.; Raison, C.L. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychaitry, 2009, 65, 732-41.
11. O'Brien, S.O.; Scott, L.V.; Dinan, T.J. Cytokines: abnormalities in major depression and implication for pharmacological treatment. Hum. Psychopharmacol. Clin. Exp., 2004, 19, 397-403.
12. Pucak, M.L.; Kaplin, A.I. Unkind cytokines: current evidence for the potential role of cytokines in immune-mediated depression. Int. Rev. Psychiatry, 2005, 17, 6, 477-83.
13. McNally, L.; Bhagwagar, Z.; Hannestad, J. Inflammation, glutamate, and glia in depression: a literature review. CNS Spectr., 2008, 13, 501-10.
14. Rudisch, B.; Nemeroff, C.B. Epidemiology of comorbid coronary artery disease and depression. Biol. Psychiatry, 2003, 54, 227-40.
15. Kessler, R.C.; McGonagle, K.A.; Zhao, S.; Nelson, C.B.; Hughes, M.; Eshleman, S.; Wittchen, H.U.; Kendler, K.S. Lifetime and 12- month prevalence of DSM IIIR psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psych., 1994; 51: 8-19.
16. Blazer, D.G; Kessler, R.C.; McGonagle, K.A., Swarz, M.S. The Prevalence and Distribution of Major Depression in a National Community Sample: the National Comorbidity Survey. Am. J. Psychiatry, 1994, 151, 979-86.
17. Frasure-Smith, N.; Lesperance, F.; Talajic, M. Depression following myocardial infarction. Impact on 6-month survival. JAMA, 1993, 270, 1819-25.
18. Robinson, R.G.; Starr, L.B.; Price, T.R. A two-year longitudinal study of mood disorders following stroke. Prevalence and duration at six month follow-up. Br J Psychiatry., 1984, 144, 256-62.
19. Sano, M.; Stern, Y.; Williams, J.; Cote, L.; Rosenstein, R.; Mayeus, R. Co-existing dementia and depression in Parkinson's disease. Arch Neurol., 1989, 46, 1284-86.
20. Greenwald, B.S.; Kramer-Ginsberg, E.; Marin, D.B. Dementia with co-existent major depression. Am. J. Psychiatry, 1989, 146, 1472-78.
21. Goodnick, P.J.; Henry, J.H.; Buki, V.M. Treatment of depression in patients with diabetes mellitus. J Clin Psychiatry., 1995, 56, 128-36.
22. Kathol, R.G.; Muigi, A.; Williams, J.; Clamon, G.; Noyes, R. Jr. Diagnosis of major depression in cancer patients according to four sets of criteria. Am J psychiatry., 1990, 147, 1021-24.
23. Hotopf, M.; Chidgey, J.; Addington-Hall, J.; Ly, K.L. Depression in advanced disease: A systematic review. Part I. Prevalence a case finding. Palliat Med., 2002, 16, 81-97.
24. Sutor, B.; Rummans, T.A.; Jowsey, S.G.; Krahn, L.E.; Martin, M.J.; O'Connor, M.K.; Philbrick, K.L.; Richardson, J.W. Major depression in medically ill patients. Mayo Clinic Proc., 1998, 73, 329-37.
25. Schleifer, S.J.; Marcari-Hinson, M.M.; Coyle, D.A.; Slater, W.R.; Kahn, M.; Gorlin, R.; Zucker, H.D. The nature and course of depression following myocardial infarction. Arch Inter Med., 1989, 149, 1785-89.
26. Carney, R.M.; Rich, M.W.; Freedland, K.E.; Saini, J. Major depressive disorder predicts cardiac events in patients with coronary artery disease. Psychosom Med., 1988, 50, 627-33.
27. Gonzalez, M.B.; Snyderman, T.B.; Colket, J.T.; Arias, R.M.; Jiang, J.W.; O'Connor, C.M.; Krishman, K.R. Depression in patients with coronary artery disease. Depression., 1996, 4, 57-62.
28. Jorge, R.E.; Robinson, R.G.; Arndt, S.; Starkstein, S. Mortality and post stroke depression: a placebo-controlled trial of antidepressants. Am. J. Psychiatry, 2003, 160, 1823-29.
29. Corti, R.; Fuster, V.; Badimon, J.J. Pathogenetic concepts of acute coronary syndromes. J. Am. Coll. Cardiol., 2003, 41, 7S-14S.
30. Ridker, P.M.; Hennekens, C.H.; Buring, J.E.; Rifai, C. C-reactive protein and other markers of inflammation: the prediction of cardiovascular disease in women. N Engl J Med., 2000, 342, 836-43.
31. Ridker, P.M.; Rifai, N.; Stampfer, M.J.; Hennekens, C.H. Plasma concentrations on Interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation, 2000, 101, 1767-72.
32. Anda, R.; Williamson, D.; Jones, D.; Macera, C.; Esker, E.; Glassman, A.; Marks, J. Depressed affect, hopelessness, and the risk of ischemic heart disease in a cohort of U.S. adults. Epidemiology., 1993, 4, 285-94.
33. Ford, D.E.; Mead, L.A.; Chang, P.P.; Cooper-Patrick, L.; Wang, N.Y.; King, M.J. Depression is a risk factor for coronary artery disease in men: the precursors study. Arch. Intern. Med., 1998, 158, 1422-26.
34. Penninx, B.W.; Beckman, A.T.; Honig, A.; Deeg, D.J.; Schoevers, R.A.; Van Eijk, J.T.; van Tiburg, W. Depression and cardiac mortality. results from a community based longitudinal study. Arch. Gen. Psychiatry, 2001, 58, 221-27.
35. Pratt, L.A.; Ford, D.E.; Crum, R.M.; Armenian, H.K.; Gallo, I.J.; Eaton, W.W. Depression, psychotropic medication, and risk of myocardial infarction. prospective data from the Baltimore ECA follow-up. Circulation, 1996, 94, 3123-29.
36. Morris, P.; "Association of Depression with 10-year Post Stroke Mortality." Am. J. Psychiatry, 1993, 150, 124-29.
37. Anderson, R.J.; Freedland, K.E.; Clouse, R.E.; Lustman, P.J. The prevalence of comorbid depression in adults with diabetes: a metaanalysis. Diabetes Care, 2001, 24, 1069-78.
38. Lustman, P.J.; Anderson, R.J.; Freedland, K.E.; de Groot, M.; Carney, R.M.; Clouse, R.E. Depression and poor glycemic control: a meta-analytic review of the literature. Diabetes Care, 2000, 23, 934-42.
39. Smith, R.S. The macrophage theory of depression. Med Hypothesis., 1991, 35, 298-306.
40. Anisman, H.; Merali, Z.; Poutler, M.S.; Hayley, S. Cytokines as a precipitant of depressive illness: animal and human studies. Curr. Pharm. Des., 2005, 11, 963-72.
41. Frommberger, U.H.; Bauer, J.; Haselbauer, P.; Fraulin, A.; Riemann, D.; Berger, M. Interleukin-6-(il-6) plasma levels in depression and schizophrenia: comparison between acute state and after transmission. Eur. Arch. Psychiatr. Clin. Neurosci., 1997, 247, 228-33.
42. Levine, J.; Barak, Y.; Chengappa, K. N.; Bening-Abu-Shach, U.; Vedder, H. Cerebrospinal cytokine levels in patients with acute depression. Neuropsychobiology, 1999, 40, 171-76.
43. Schiepers, O. J.; Wichers, M. C.; Maes, M. Cytokines and major depression. Prog. Neuropsychopharm. Biol. Psychiatr., 2005, 29, 201-17.
44. Lanquillon, S.; Krieg, J. C.; Bening-Abu-Shach, U.; Vedder, H. Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacol., 2000, 29, 370-79.
45. Mohr, D. C.; Goodkin, D. E.; Islar, J.; Hauser, S. L.; Genain, C.P. Treatment of depression is associated with suppression of nonspecific and antigen-specific T(H)1 receptors in multiple sclerosis. Arch. Neurol., 2001, 58, 1081-86.
46. Yirmiya, R.; Weidenfeld, J.; Pollak, Y.; Morag, M.; Morag, A.; Avisur, R.; Barak, O.; Reichenberg, A.; Cohen, E.; Shavif, Y.; Ovadia, H. Cytokines, "depression due to a medical condition," and antidepressant drugs. Adv. Exp. Med. Biol., 1999, 461, 283-316.
47. Anisman, H.; Ravindran, A. V.; Griffiths, J.; Merali, Z. Interleudin-1 beta production in dysthymia before and after pharmacotherapy. Biol. Psychiatry, 1999, 46, 1649-55.
48. Zorilla, E. P.; Luborsky, L.; McKay, J. R.; Rosenthal, R.; Houldin, A.; Rax, A.; McCorkle, R.; Seligman, D.A.; Schmidt, K. The relationship of depression and stressors to immunological assays: a meta-analytical review. Brain Behav. Immun., 2001, 15, 199-226.
49. Mossner, R.; Mikova, O.; Koutsilieri, E.; Saoud, M.; Ehils, A. C.; Muller, N.; Fallgatter, A.J.; Riederer, R. Consensus paper of the WFSBP task force on biological markers: biological markers in depression. World J. Biol. Psychiatry, 2007, 8, 141-74.
50. Maes, M. Major depression and activation of the inflammatory response system. Adv. Exp. Med. Biol., 1999, 461, 25-46.
51. Song, C.; Dinan, T.G.; Leonard, B.E. Changes in immunoglobulin, complement and acute phase protein levels in the depressed patients and normal controls. J. Affect. Disord., 1994, 30, 283-88.
52. Musselman, D. L.; Miller, A. H.; Porter, M. R.; Manatunga, A.; Gao, F.; Penna, S.; Pearce, B.D.; Landry, J.; Glover, S.; McDaniel, J.S.; Nemeroff, C.B. Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: preliminary findings. Am. J. Psychiatry, 2001, 158, 1252-57.
53. Kent, S.; Bluthe, R. M.; Kelley, K.W.; Dantzer R. Sickness behavior as a new target for drug development. Trends Pharmacol. Sci., 1992, 13, 24-28.
54. Reichenberg, A.; Yirmiya, R.; Schuld, A.; Kraus, T.; Haack, M.; Morag, A. cytokine-associated emotional and cognitive disturbances in humans. Arch. Gen. Psychiatr., 2001, 58, 445-52.
55. Raison, C.L.; Borisov, A.S.; Majer, M.; Drake, D.; Pagnoni, G.; Woolwine, B. Activation of central nervous system inflammatory pathways by interferon-alpha: relationship to monoamines and depression. Biol. Psychiatr., 2009, 65, 296-303.
56. Quan, N.; Banks, W.A. Brain-immune communication pathways. Brain Behav. Immun., 2007, 21, 727-35.
57. Reyes, T. M.; Coe, C.L. Interluekin-1 beta differentially affects interleukin-6 and soluble interleukin-6 receptor in the blood and central nervous system of the monkey. J Neuroimmunol., 1996, 66, 135-41.
58. Kendler, K.S.; Gardner, C.O.; Prescott, C.A. Toward a comprehensive developmental model for major depression in women. Am. J. Psychiatry, 2002, 150, 1133-45.
59. Maes, M.; Lin, A.H.; Delmeire, L.; Van Gastel, A.; Kenis, G.; De Jongh, R. Elevated serum interleukin-6 (IL-6) and IL-6 receptor concentrations in post-traumatic stress disorder following accidental man-made traumatic events. Biol. Psychiatr., 1999, 45, 833-39.
60. Maes, M.; Song, C.; Lin, A.; De Jongh, R.; Van Gastel, A.; Kenis, G. The effects of psychological stress on humans: increased production of pro-inflammatory cytokines and a Th-1 like response in stress-induced anxiety. Cytokine, 1998, 10, 313-18.
61. Brydon, L.; Edwards S.; Mohamed-Ali, V.; Steptoe, A. Socioeconomic status and stress-induced increases in interleukin-6. Brain Behav. Immun., 2004, 18, 281-90.
62. Bierhaus, A.; Wolf, J.; Andrassy, M.; Rohleder, N.; Humpert, P.M.; Petrov, D.; Ferstl, R.; von Eynatren, M.; Wendt, T.; Rudofsky, G.; Joswig, M.; Morcos, M.; Schwaninger, M.; McEwen, B.; Kirschbaum, C.; Norwroth, P.P. A mechanism converting psychosocial stress into mononuclear cell activation. Proc. Nat. Acad. Sci. USA, 2003, 100, 1920-25.
63. McDade, T.W.; Hawkley, L.C.; Cacioppo, J.T. Psychosocial and behavioral predictors of inflammation in middle-aged and older adults: the Chicago health, aging and social relations study. Psychosom. Med., 2006, 68, 376-81.
64. Kiecolt-Glaser, J.K.; Loving, T.J.; Stowell, J.R.; Malarkey, W.B.; Lemeshow, S.; Dickinson, S.L. Hostile marital interactions, proinflammatory cytokine production, and wound healing. Arch. Gen. Psychiatr., 2005, 62, 266-72.
65. Pace, T.W.W.; Mletzko, T.C.; Alagbe, O.; Musselman, D.L.; Nemeroff, C.B.; Miller, A.H.; Heim, C.M. Increased stress-induced inflammatory response in male patients with major depression and increased early life stress. Am. J. Psychiatr., 2006, 163, 1630-33.
66. Danese, A.; Pariante, C.M.; Caspi, A.; Taylor, A.; Poulton, R. Childhood maltreatment predicts adult inflammation in a lifecourse study. Proc. Natl. Acad. Sci. USA, 2007, 104, 1319-24.
67. Chrousos, G.P. The hypothalamic-pituitary-adrenal-axis and immune- mediated inflammation. N. Engl. J. Med., 1995, 332, 1351-62.
68. Pariante, C.M.; Pearce, B.D.; Pisell, T.L.; Sanchez, C.I.; Po, C.; Su, C.; Miller, A.H. The proinflammatory cytokine, interleukin-1 alpha, reduces glucocorticoid receptor translocation and function. Endocrinology, 1999, 140, 4359-66.
69. Taylor, J.L.; Grossberg, S.E. The effects of interferon-alpha on the production and action of other cytokines. Semin. Oncol., 1998, 25, 23-9.
70. Raison, C.L.; Borisov, A.S.; Broadwell, S.D.; Capuron, L.; Woolwine, B.J; Jacobson, I.M.; Nemeroff, C.B. Miller, A.H. Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. J. Clin. Psychiatr., 2005, 66, 41-8.
71. Capuron, L.; Guminck, J.F.; Musselman, D.L.; Lawson, D.H.; Reemsnyder, A.; Nemeroff, C.B.; Miller, A.H. Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology, 2002, 26, 643-52.
72. Felger, J.F.; Alagbe, O.; Hu, F.; Mook, D.; Freeman, A.A.; Sanchez, M.M.; Kalin, N.H.; Ratti, E.; Nemeroff, C.B.; Miller, A.H. Effects of interferon-alpha on rhesus monkeys: a nonhuman primate model of cytokine-induced depression. Biol. Psychiatry, 2007, 62, 1324-33.
73. Miyaoka, H.; Otsubo, T.; Kamijima, K.; Ishii, M.; Onuki, M.; Mitamura, K. Depression from interferon therapy in patients with hepatitis C. Am. J. Psychiatr., 1999, 156, 20.
74. Musselman, D.L.; Lawson, D.H.; Gumnick, J.F.; Manatunga, A.K.; Penna, S.; Goodkin, R.S.; Greiner, K.; Nemeroff, C.B.; Miller, A.H. Paroxetine for the prevention of depression induced by highdose interferon-alpha. N. Engl. J. Med., 2001, 344, 961-66.
75. Rankine, E.L.; Hughes, P.M.; Botham, M.S.; Perry, V.H.; Felton, L.M. Brain cytokine synthesis induced by an intraparenchymal injection of LPS is reduced in MCP-1 deficient mice prior to leukocyte recruitment. Eur. J. Neurosci., 2006, 24, 77-86.
76. Dentino, A.N.; Pieper, C.F.; Rao, K.M.K. Association of interleukin-6 and other biological variables of depression in older people living in the community. J. Am. Geriatr. Soc., 1999, 47, 6-11.
77. Maes, M.; Bosmans E.; Meltzer, H.Y. Immuno-endocrine aspects of major depression: relationships between interleukin-6 and soluble interleukin-2receptor, prolactin, and cortisol. Eur. Arch. Psychiatr. Clin. Neurosci., 1995, 24, 172-78.
78. Maes, M.; Scharpe, S.; Meltzer, H.Y.; Bosmans, E.; Suy, E.; Calabrese, J. Relationships between interleukin-6 activity, acute phase proteins, and function of the hypothalamic-pituitary-adrenal axis in severe depression. Psychiatr. Res., 1993, 49, 11-27.
79. Pearlstein, R.S.; Whitnall, M.H.; Abrams, J.S.; Mougey, E.H.; Neta, R. Synergistic roles of interleukin-6, interleukin-1, and tumor necrosis factor in the adrenocorticotropin release to lipopolysaccharide in vivo. Endocrinology, 1993, 132, 945-52.
80. Capuron, L.; Raison, C.L.; Musselman, D.L.; Lawson, D.H.; Nemeroff, C.B.; Miller, A.H. Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy. Am. J. Psychiatr., 2003, 160, 1342-45.
81. Ramamorthy, S.; Ramamorthy, J.D.; Prasad, P.D.; Bhat, G.K.; Mahesh, V.B.; Leibach, F.H. Regulation of the human serotonin transporter by interleukin-1 beta. Biochem. Biophys. Res. Commun., 1995, 216, 560-67.
82. Morikawa, O.; Sakai, N.; Obara, H.; Saito, N. Effects of interferonalpha, interferon-gamma,and cAMP on the transcriptional regulation of the serotonin transporter. Eur. J. Pharmacol., 1998, 349, 317-24.
83. Mossner, R.; heils, A.; Stober, G.; Okladnova, O.; Daniel, S.; Lesch, K.P. Enhancement of serotonin transporter function by tumor necrosis factor-alpha but not interleukine-6. Neurochem. Int., 1998, 33, 251-54.
84. Bell, C.; Abrams, J.; Nutt, D. Tryptophan depletion and its implications in psychiatry. Br. J. Psychiatry, 2001, 178, 399-405.
85. Heyes, M.P.; Crowley, J.S.; Davis, L.E. Quinolinic acid and kynurenine pathway metabolism in inflammatory and noninflammatory neurological disease. Brain, 1992, 115, 1249-73.
86. Capuron, L.; Neurauter, G.; Musselman, D.L.; Lawson, D.H.; Nemeroff, C.B.; Fuchs, D. Interferon-alpha induced changes in tryptophan metabolism: Relationship to depression and paroxetine treatment. Biol. Psychiatry, 2003, 54, 906-14.
87. Kumal, T.; Tateshi, T.; Tamaka, M.; Watahabe, M.; Sjormizu, H.; Kobayasi, S. Effects of interferon-alpha on tyrosine hydroxylase and catecholeamine levels in the brains of rats. Life Sci., 2000, 67, 663-69.
88. Shuto, H.; Kataoka, Y.; Horikawa, T.; Fujihara, N.; Oishi, R. Repeated interferon-alpha administration inhibits dopaminergic neural activity in the mouse brain. Brain Res., 1997, 747, 348-51.
89. McKinney, W.T.; Eisling, R.G.; Moran, E.C.; Suomi, S.J.; Harlow, H.F. Effects of reserpine on the social behavior of rhesus monkeys. Dis. Nerv. Syst., 1971, 32, 735-41.
90. Fedele, E.; Foster, A.C. n evaluation of the role of extracellular amino acids in the delayed neurodegeneration induced by quinolinic acid in the rat striatum. Neuroscience, 1993, 52, 911-17.
91. Danbolt, N.C. Glutamate uptake. Prog. Neurobiol., 2001, 65, 1-105.
92. Frizzo, M.E.; Dall'Onder, L.P.; Dalcin, K.B.; Souza, D.D. Riluzole enhances glutamate in rat astrocyte cultures. Cell. Mol. Neurobiol., 2004, 24, 123-28.
93. Sheline, Y.L.; Wang, P.W.; Gado, M.H.; Csernansky, J.G.; Vannier, M.W. Hippocampal atrophy in recurrent major depression. Proc. Natl. Acad. Sci. USA, 1996, 93, 3908-13.
94. Gould, E.; Tanapar, P.; McEwen, B.S.; Flugge, G.; Fuchs, E. Proliferation of granule cell precursors in the dentate gyrus of adult monkeys is diminished by stress. Proc. Natl. Acad. Sci. USA, 1998, 95, 3168-71.
95. Koo, J.W.; Duman, R.S. IL-1 beta is an essential mediator of the antineurogenic and anhedonic effects of stress. Proc. Natl. Acad. Sci. USA, 2008, 105, 751-56.
96. Wu, C.W, Chen, Y.C.; yu, L.; Chen, H.I.; Jen, C.I.; Huang, A.M. Treadmill exercise counteracts the suppressive effects of peripheral lipopolysaccharide on hippocampal neurogenesis and learning and memory. J. Neurochem., 2007, 103, 2471-81.
97. Vallieres, L.; Campbell, I.L.; Gage, F.H.; Sawchenko, P.E. Reduced hippocampal neurogenesis in adult transgenic mice with chronic astrocytic production of interleukin-6. J. Neurosci., 2002, 22, 486-92.
98. Martinowich, K.; Mangi, H.; Lu, B. New insights into BDNF function in depression and anxiety. Nat. Neurosci., 2007, 10, 1089-93.
99. Fatemi, S.H.; Laurence, J.A.; Araghi-Niknam, M. Glial fibrillary acidic proteins reduced in cerebellum of subjects with major depression, but not schizophrenia. Schizophr. Res., 2004, 69, 317-23.
100. Si, X.; Miguel-Hidalgo, J.J.; O'Dwyer, G.; Stockmeier, C.A.; Rajkowska, G. Age-dependent reductions in the level of glial fibril lary acidic protein in the prefrontal cortex in major depression. Neuropsychopharmacology, 2004, 29, 2088-96.
101. Capuron, L.; Pagnoni, G.; Dematrashvil, M.F.; Lawson, D.H.; Formwalt, F.B.; Woolwine, B.; Berns, G.S.; Nemeroff, C.B.; Miller, A.H. Basal ganglia hypermetabolism and symptoms of fatigue during interferon-alpha therapy. Neuropyshcomarmacolgy, 2007, 32, 2384-92.
102. Brydon, L.; Harrison, N.A.; Walker, C.; Steptoe, A.; Critchley, H.D. Peripheral inflammation is associated with altered substantia nigra activity and psychomotor slowing in humans. Biol. Psychiatry, 2008, 63, 1022-29.
103. Capuron, L.; Pagnoni, G.; Dematrashvil, M.F.; Woolwine, B.; Nemeroff, C.B.; Berns, G.S.; Miller, A.H. Anterior cingulate activation and error processing during interferon-alpha treatment. Biol. Psychiatr., 2005, 58, 190-96.
104. Paulus, M.P.; Feinstein, J.S.; Simmons, A.; Stein, M.B. Anterior cingulate activation in high trait anxious subjects is related to altered error processing during decision making. Boil. Psychiatr., 2004, 55, 1179-87.
105. Lewis, D.A.; Foote, S.L.; Cha, C.I. Corticotropin-releasing factor immunoreactivity in monkey neocortex: an immunohistochemical analysis. J. Comp. Neurol., 1989, 290, 599-613.
106. Gabriel, M.; Taylor, C. Prenatal exposure to cocaine impairs neuronal coding of attention and discriminate learning. Ann. NY Acad. Sci., 1998, 846, 194-212.
107. Juengling, F.D.; Ebert, D.; Gut, O. Prefrontal cortical hypometaboilsm during low-dose interferon-alpha treatment. Psychopharmacology, 2000, 152, 383-89.
108. Tanaka, H.; Maeshima, S.; Shigekawa, Y. Neuropsychological impairment and decreased regional cerebral blood flow by interferon treatment in patients with chronic hepatitis: a preliminary study. Clin. Exp. Med., 2006, 6, 124-28.
109. Muller, N.; Schwarz, M.J.; Dehning, S.; Douhet, A.; Cerovecki, A.; Goldstein-Muller, S.; Spellman, I.; Hetzel, G.; Maino, K.; Kleindeniest, N.; Moller, H.J.; Arolt, V.; Reidel, M. The cylcooxygenas-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebocontrolled, add-on pilot study to reboxetine. Mol. Psychiatry, 2006, 11, 680-84.
110. Tyring, S.; Gottleib, A.; Papp, K.; Gordon, K.; Leonardi, C.; Wang, A.; Lalla, D.; Woolley, M.; Jahreis, A.; Zitnik, R.; Cella, D.; Krishnan, R. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomized phase III trial. Lancet, 2006, 367, 29-35.
111. Casolini, P.; Catalini, A.; Zuena, A.R.; Angelucci, L. Inhibition of Cox-2 reduces the age-dependent increase of hippocampal inflammatory markers, corticosterone secretion, and behavioral impairments in the rat. J. Neurosci. Res., 2002, 68, 337-43.
112. Connor, T.J.; Harkin, A.; Kelly, J.P.; Leonard, B.Olfactory bulbectomy provokes a suppression of interleukin-1 beta and tumor necrosis factor-alpha production in response to an in vivo challenge with lipopolysaccharide: effect of chronic desipramine treatment. Neuroimmunomodulatory, 2000, 7, 27-35.
113. Xia, Z.; De Poere, J.W.; Nassberger, L. TCA's inhibit IL-1, IL-6, and TNF release in human blood monocytes and IL-2 and interferon in T-cells. Immunopharmacolog, 1996, 24, 27-37.
114. Levenson, J.L.; Fallon, H.J. Fluoxetine treatment of depression caused by interferon-alpha. Am. J. Gastroenterol., 1998, 88, 760-61.
115. Gleason, O.C.; Yates, W.R. Five cases of interferon-alpha-induced depression treated with antidepressant therapy. Psychsosomatics, 1999, 40, 510-12.
116. Leonard, B.E. The immune system, depression and the actionof antidepressants. Prog. Neuro-psychopharmacol. Biol. Psychiatry, 2001, 25, 767-80.
117. Mohr, D.C.; Goodkin, D.C.; Islar, J.; Hauser, S.L.; Genain, C.P. Treatment of depression is associated with suppression of nonspecific and antigen-specificT(H)1 responses in multiple sclerosis. Arch. Neurol., 2001, 58, 1081-86.
118. Sluzewaska, A.; Rybakowski, J.K.; Laciak, M.; Mackiewicz, A.; Sobieska, M.; Wiktorowicz, K. Interleukin-6 serum levels in depressed patients before and after treatement with fluoxetine. Am. NY Acad. Sci., 1995, 762, 474-76.
119. O'Brien, S.; Scott, L.V.; Dinan, T.g. Antidepressant therapy and Creactive protein levels. Br. J. Psychiatry, 2006, 188, 449-52.
120. O'Brien, S.; Scully, P.; Fitzgerald, P.; Plasma cytokine profile in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy. J. Psychiatr. Res., 2007, 41, 326-31.
121. Maes, M.; Bosmans, E, De Jongh, R, Kenis, G.; Vandoolaeghe, E.; Neels, H. Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine, 1997, 9, 853-58.
122. Elier, T.; Vasar, V.; Shlik, J.; Maron, E. Proinflammatory cytokines and treatment response to escitalopram in major depressive disorder. Biol. Psychiatry, 2008, 32, 445-50.